Toll Free: 1-888-928-9744

Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 97 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016', provides in depth analysis on Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted pipeline therapeutics. 

The report provides comprehensive information on the Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC)
- The report reviews Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) Overview 10 Therapeutics Development 11 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Stage of Development 11 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Therapy Area 12 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Indication 13 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Companies 18 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Universities/Institutes 25 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Therapeutics Assessment 27 Assessment by Monotherapy/Combination Products 27 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Companies Involved in Therapeutics Development 33 4SC AG 33 Advinus Therapeutics Ltd. 34 Arrien Pharmaceuticals, LLC 35 Aurigene Discovery Technologies Limited 36 Biogen, Inc. 37 Brickell Biotech, Inc. 38 Bristol-Myers Squibb Company 39 Celgene Corporation 40 Genentech, Inc. 41 Genfit SA 42 GlaxoSmithKline Plc 43 Hanmi Pharmaceuticals, Co. Ltd. 44 Karo Bio AB 45 Lead Pharma Holding B.V. 46 Nuevolution AB 47 Phenex Pharmaceuticals AG 48 Reata Pharmaceuticals, Inc. 49 Teijin Pharma Limited 50 Visionary Pharmaceuticals, Inc. 51 Vitae Pharmaceuticals, Inc. 52 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Drug Profiles 53 ARN-6039 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 BBI-6000 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 GSK-2981278 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 INV-17 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecule to Agonize ROR-Gamma for Inflammation and Oncology - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Autoimmune Disorders and Inflammation - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Small Molecules to Antagonize ROR-Gamma T for Autoimmune Disorders - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Small Molecules to Antagonize RORC for Multiple Sclerosis, Immunology and Non-Alcoholic Steatohepatitis - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Small Molecules to Inhibit ROR-Gamma for Inflammation - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Small Molecules to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Small Molecules to Target ROR Gamma - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Small Molecules to Target ROR gamma for Autoimmune Diseases - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 SR-1001 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 TGFTX-1 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 TMP-778 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 VPR-66 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 VTP-43742 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Dormant Projects 84 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Discontinued Products 85 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Featured News & Press Releases 86 Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis 86 Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742 87 Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting 87 Nov 02, 2015: Lead Pharma Achieves first Milestone for Development of Autoimmune Diseases Treatments in Research Collaboration with Sanofi 88 Sep 29, 2015: Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients 89 Sep 08, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders 89 Aug 10, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders 90 Aug 05, 2015: Aurigene to Present its RORg Inverse Agonist Program at World Congress on Inflammation, 2015 91 Jun 29, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders 91 Apr 16, 2015: Vitae Pharmaceuticals to Present at Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases 91 Mar 17, 2015: New Compound Prevents Type 1 Diabetes in Animal ModelsóBefore It Begins 92 Feb 09, 2015: Lycera Announces Research Showing Promising Anti-Cancer Activity of Novel, Oral Immunotherapy Candidates 93 Jan 05, 2015: Lycera Scientists Identify Endogenous Agonists for ROR that control Th17 Cell Differentiation 93 Nov 07, 2014: Lycera Announces Research Showing Novel, Oral Immunotherapy Possesses Potent Single Agent Anti-Cancer Activity 94 Nov 05, 2014: Innovimmune to Present Superior Preclinical Therapeutic Efficacy Results in Rheumatoid Arthritis of Its INV-17 ROR Gamma t Inhibitor Program at the 2014 American College of Rheumatology Annual Meeting 95 Appendix 96 Methodology 96 Coverage 96 Secondary Research 96 Primary Research 96 Expert Panel Validation 96 Contact Us 96 Disclaimer 97
List of Tables
Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Indication, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Comparative Analysis by Unknown Stage Development, H1 2016 17 Number of Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Development by Companies, H1 2016 (Contd..2) 22 Products under Development by Companies, H1 2016 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H1 2016 25 Products under Investigation by Universities/Institutes, H1 2016 26 Assessment by Monotherapy/Combination Products, H1 2016 27 Number of Products by Stage and Mechanism of Action, H1 2016 29 Number of Products by Stage and Route of Administration, H1 2016 31 Number of Products by Stage and Molecule Type, H1 2016 32 Pipeline by 4SC AG, H1 2016 33 Pipeline by Advinus Therapeutics Ltd., H1 2016 34 Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 35 Pipeline by Aurigene Discovery Technologies Limited, H1 2016 36 Pipeline by Biogen, Inc., H1 2016 37 Pipeline by Brickell Biotech, Inc., H1 2016 38 Pipeline by Bristol-Myers Squibb Company, H1 2016 39 Pipeline by Celgene Corporation, H1 2016 40 Pipeline by Genentech, Inc., H1 2016 41 Pipeline by Genfit SA, H1 2016 42 Pipeline by GlaxoSmithKline Plc, H1 2016 43 Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 44 Pipeline by Karo Bio AB, H1 2016 45 Pipeline by Lead Pharma Holding B.V., H1 2016 46 Pipeline by Nuevolution AB, H1 2016 47 Pipeline by Phenex Pharmaceuticals AG, H1 2016 48 Pipeline by Reata Pharmaceuticals, Inc., H1 2016 49 Pipeline by Teijin Pharma Limited, H1 2016 50 Pipeline by Visionary Pharmaceuticals, Inc., H1 2016 51 Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 52 Dormant Projects, H1 2016 84 Discontinued Products, H1 2016 85


List of Figures
Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Top 10 Indication, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 27 Number of Products by Mechanism of Actions, H1 2016 28 Number of Products by Stage and Mechanism of Actions, H1 2016 28 Number of Products by Routes of Administration, H1 2016 30 Number of Products by Stage and Routes of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiency

Read More...

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...

Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growt

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify